FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
|Articles|April 1, 2016
- Pharmaceutical Executive-04-01-2016
- Volume 36
- Issue 4
Pharmaceutical Executive, April 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 10 years ago
Closing the Gaps in Drug Chain of Custodyover 10 years ago
Data Unleashed: Cooperation Among Competitorsover 10 years ago
Raising the Stakes On Value-Based Pricingover 10 years ago
The Diversity Dearth in Pharmaover 10 years ago
Information in Action: A Conversation with Barbara Lopez Kunzover 10 years ago
R&D Model Mixes Compassion, Calculationover 10 years ago
Pressure Builds to Revamp Off-Label Marketing Rulesover 10 years ago
Drug Compounding: A Cause and Cure for High Drug Prices?over 10 years ago
The Odd Coupleover 10 years ago
Country Report: EgyptAdvertisement
Related to this article
Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.
Six years after Rutledge, new court rulings, federal PBM reforms, and state ownership bans are redrawing the limits of pharmacy benefit regulation.
Adding oral L-glutamine to standard chemo nearly tripled median OS in advanced pancreatic cancer — and what comes next.
Numerof's Michael Abrams on why healthcare consolidation is the primary driver of rising employer costs — and why there's no end in sight.
InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.
Eli Lilly is set to pay InnoCare Pharma up to $3.35 billion to discover and develop compounds against upwards of five undisclosed targets.
FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Onswik for Adults with Type 2 Diabetes
2
What Actually Went Wrong When a Phase 3 Trial Fails: Q&A with Dr. Remo Moomiaie-Qajar
3
The Legacy of Rutledge: How States and Congress Can Still Regulate Pharmacy Benefit Managers
4
Novartis & BoomRay Enter Global License Agreement for Preclinical Radioligand Asset
5